![Jennifer Swettenham](https://profiles-cardiff.imgix.net/attachments/1230?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Jennifer Swettenham
Neuroscience Portfolio Manager
School of Biosciences
Overview
I am the Neuroscience Portfolio Manager working in the Medicines Discovery Institute at Cardiff University. I manage the neuroscience drug discovery projects, liaising and collaborating with our research partners to ensure project milestones are delivered.
I project manage the First-In-Human Phase 1 clinical trial of MDI-26478 - a novel compound being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS). This trial will test the safety and tolerability of MDI-26478 in healthy volunteers, and the trial will also use the neuroimaging facilities at CUBRIC to show how MDI-26478 affects the brain.
Previously, I was a Clinical Trial Manager in the Cancer Group of the Centre for Trials Research (CTR). There I developed and managed early phase trials, mainly in gynaecological cancers. Prior to that, I was the trial manager for research investigating disorders of localised fibrosis at the Oxford Clinical Trials Research Unit (OCTRU), and the Infectious Diseases Trial Co-ordinator at the Primary Care Clinical Trials Unit (University of Oxford).
My background is in neuroscience and I have more than ten years’ experience of running human behavioural and neuroimaging (magnetoencephalography (MEG) and magnetic resonance imaging (MRI)) studies. My postdoctoral research at CUBRIC (Cardiff University Brain Research Imaging Centre) investigated visual processing in the brain. Then, as Research Facilitator at OHBA (Oxford centre for Human Brain Activity), I trained researchers and helped them develop their studies. I have worked on many studies covering a wide range of cognitive processes in both the healthy and non-typical brain.
Publication
2018
- Nanchahal, J. et al. 2018. Anti-tumour necrosis factor therapy for Dupuytren's Disease: a randomised dose response proof of concept phase 2a clinical trial. EBioMedicine 33, pp. 282-288. (10.1016/j.ebiom.2018.06.022)
2017
- Nanchahal, J. et al. 2017. Study protocol: a multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.. Wellcome Open Research 2, pp. 37. (10.12688/wellcomeopenres.11466.1)
2013
- Swettenham, J., Muthukumaraswamy, S. D. and Singh, K. D. 2013. BOLD responses in human primary visual cortex are insensitive to substantial changes in neural activity. Frontiers in Human Neuroscience 7, article number: 76. (10.3389/fnhum.2013.00076)
2010
- Muthukumaraswamy, S. D., Singh, K. D., Swettenham, J. B. and Jones, D. K. 2010. Visual gamma oscillations and evoked responses: Variability, repeatability and structural MRI correlates. NeuroImage 49(4), pp. 3349-3357. (10.1016/j.neuroimage.2009.11.045)
- Swettenham, J. B., Anderson, S. J. and Thai, N. J. 2010. MEG responses to the perception of global structure within glass patterns. PLoS ONE 5(11), article number: e13865. (10.1371/journal.pone.0013865)
2009
- Swettenham, J. B., Muthukumaraswamy, S. D. and Singh, K. D. 2009. Spectral properties of induced and evoked gamma oscillations in human early visual cortex to moving and stationary stimuli. Journal of Neurophysiology 102(2), pp. 1241-1253. (10.1152/jn.91044.2008)
- Muthukumaraswamy, S. D., Edden, R. A. E., Jones, D. K., Swettenham, J. B. and Singh, K. D. 2009. Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans. Proceedings of the National Academy of Sciences of the United States of America 106(20), pp. 8356-8361. (10.1073/pnas.0900728106)
2007
- Hadjipapas, A., Adjamian, P., Swettenham, J. B., Holliday, I. E. and Barnes, G. R. 2007. Stimuli of varying spatial scale induce gamma activity with distinct temporal characteristics in human visual cortex. NeuroImage 35(2), pp. 518-530. (10.1016/j.neuroimage.2007.01.002)
2006
- Anderson, S. J. and Swettenham, J. B. 2006. Neuroimaging in human amblyopia. Strabismus 14(1), pp. 21-35. (10.1080/09273970500538082)
Articles
- Nanchahal, J. et al. 2018. Anti-tumour necrosis factor therapy for Dupuytren's Disease: a randomised dose response proof of concept phase 2a clinical trial. EBioMedicine 33, pp. 282-288. (10.1016/j.ebiom.2018.06.022)
- Nanchahal, J. et al. 2017. Study protocol: a multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.. Wellcome Open Research 2, pp. 37. (10.12688/wellcomeopenres.11466.1)
- Swettenham, J., Muthukumaraswamy, S. D. and Singh, K. D. 2013. BOLD responses in human primary visual cortex are insensitive to substantial changes in neural activity. Frontiers in Human Neuroscience 7, article number: 76. (10.3389/fnhum.2013.00076)
- Muthukumaraswamy, S. D., Singh, K. D., Swettenham, J. B. and Jones, D. K. 2010. Visual gamma oscillations and evoked responses: Variability, repeatability and structural MRI correlates. NeuroImage 49(4), pp. 3349-3357. (10.1016/j.neuroimage.2009.11.045)
- Swettenham, J. B., Anderson, S. J. and Thai, N. J. 2010. MEG responses to the perception of global structure within glass patterns. PLoS ONE 5(11), article number: e13865. (10.1371/journal.pone.0013865)
- Swettenham, J. B., Muthukumaraswamy, S. D. and Singh, K. D. 2009. Spectral properties of induced and evoked gamma oscillations in human early visual cortex to moving and stationary stimuli. Journal of Neurophysiology 102(2), pp. 1241-1253. (10.1152/jn.91044.2008)
- Muthukumaraswamy, S. D., Edden, R. A. E., Jones, D. K., Swettenham, J. B. and Singh, K. D. 2009. Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans. Proceedings of the National Academy of Sciences of the United States of America 106(20), pp. 8356-8361. (10.1073/pnas.0900728106)
- Hadjipapas, A., Adjamian, P., Swettenham, J. B., Holliday, I. E. and Barnes, G. R. 2007. Stimuli of varying spatial scale induce gamma activity with distinct temporal characteristics in human visual cortex. NeuroImage 35(2), pp. 518-530. (10.1016/j.neuroimage.2007.01.002)
- Anderson, S. J. and Swettenham, J. B. 2006. Neuroimaging in human amblyopia. Strabismus 14(1), pp. 21-35. (10.1080/09273970500538082)
Biography
Career overview
- 2019-present: Neuroscience Portfolio Manager, Medicines Discovery Institute, Cardiff University, UK.
- 2017-2019: Clinical Trial Manager, Solid Tumours, Centre for Trials Research, Cardiff University, UK.
- 2015-2017: Clinical Trial Manager, Oxford Clinical Trials Research Unit (OCTRU), University of Oxford, UK.
- 2014-2015: Clinical Trial Coordinator: Primary Care Clinical Trials Unit (PC-CTU), University of Oxford, UK.
- 2011-2014: Research Facilitator: The Oxford Centre for Human Brain Activity (OHBA), University of Oxford, UK.
- 2010-2011: Visiting Lecturer: Aston University, UK.
- 2009-2011: Post-doctoral Research Associate: Studies of autism spectrum disorder (ASD), University of Oxford, UK.
- 2006-2009: Post-doctoral Research Associate: Cardiff University Brain and Repair Imaging Centre (CUBRIC), Cardiff University, UK.
- 2000-2001: Laboratory Manager at Weston Medical Ltd., Eye, UK.
Education and qualifications
- 2001-2006: PhD: ‘Functional neuroimaging and behavioural studies on global form processing in the human visual system’: Aston University, UK.
- 1996-2000: BSc (Hons) Neuroscience 1st Class at University of Nottingham, UK.
- 1998-1999: Industrial Placement Student at Eli Lilly and Co., Windlesham, UK.